ClinicalTrials.gg
RecruitingNCT07237685EVOLVEUpdated Nov 20, 2025

Evaluating Atherosclerotic Disease Progression in Patients With Diabetes Mellitus

An observational study in Type 2 Diabetes, Coronary Artery Disease (CAD) and Atherosclerosis Cardiovascular Disease, sponsored by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA). Recruiting at 2 sites in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-20.

Sponsored by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Observational

How we know

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Diabetes Mellitus, Type 2 by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) — 3 open to participants now, 4 under way, none of them phase 3. Diabetes Mellitus, Type 2 · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA).

Started
2025
the only one that year
Observational
2 of 12
1 open now
Registered
12th of 12
by date

Among the 12 studies in Diabetes Mellitus, Type 2 by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), this one is the only one that started in 2025, is one of 2 observational ones, and was the 12th registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 12 studies in Diabetes Mellitus, Type 2 by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Diabetes Mellitus, Type 2 by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), or all of them as a file.
02

Study summary

People with type 2 diabetes have a much higher risk of heart disease. One common problem is when the blood vessels that supply the heart become narrowed or blocked by fatty deposits, called plaque. This makes it harder for blood to reach the heart and can lead to serious problems such as chest pain, heart attacks, or even death.

This study will follow people with type 2 diabetes who have already had a special heart scan called a coronary CT angiography. This scan takes detailed pictures of the heart's blood vessels.

The goal is to understand how heart disease changes over time in people with type 2 diabetes, by looking at repeat scans and other health information. By learning more about how plaque builds up or gets worse, researchers hope to find better ways to identify which patients are most at risk for future heart problems.

03

Conditions studied

  • Type 2 Diabetes
  • Coronary Artery Disease (CAD)
  • Atherosclerosis Cardiovascular Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

In this study, patients with T2D who previously undergone CCTA for CAD assessment will be recruited. Patients will be included at three clinical sites: Amsterdam UMC, Cardiology centre Netherlands (CCN), University hospital of Salamanca - Fundacion Instituto de Estudios de ciencias de la salud de castilla y leon (IBSAL).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age over 18 years
  • Previous completion of CCTA scan for CAD assessment
  • Diagnosed with Type 2 Diabetes and currently receiving glucose lowering treatment
  • Sufficient image quality of the CCTA scan (at least 2/3 vessels of sufficient quality for assessment).

Exclusion criteria

Exclusion Criteria:

  • Inability to provide written
  • Presence of an unstable condition
  • Ingeligibility for CCTA acquisition due to severe renal dysfunction ( ≤ 30 mL/min/1.73m²) or known or to CT contrast agents
  • Any other treatment or condition that could interfere with the conduct or interpretation of the study in the opinion of the investigator
  • inability or unwillingness to comply with the protocol requirements, or deemed by investigator to be unfit for the study
  • Baseline (routine care) CCTA performed \< 2 years or > 5 years before inclusion
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,000 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. progression of total coronary plaque volume (mm3)

    The primary study parameter will be the progression of total coronary plaque volume (mm3). This will be calculated by subtracting the coronary plaque volume measured in the first CCTA from the total plaque volume measured in the follow-up CCTA. The plaque volume will be determined by dividing the total plaque volume by the total vesssel volume

    Time frame: Between baseline (retrospective) and follow up CCTA (interval 2-5 years).

Secondary outcomes

  1. Changes in Coronary Artery Disease Reporting and Data Scale(CAD-RADS) scores

    Change in the percentage of luminal narrowing per lesion as defined by the Coronary Artery Disease Reporting and Data Scale(CAD-RADS) score (minimum 0, maximum 5).

    Time frame: Between baseline (retrospective) and follow up CCTA (interval 2-5 years)

  2. Progression of calcified plaque volume (mm3)

    The progression of total calcified plaque volume

    Time frame: Baseline (retrospective) and follow up CCTA (interval 2-5 years)

  3. Progression of non-calcified plaque volume (mm3)

    The progression of total non-calcified plaque volume

    Time frame: Baseline (retrospective) and follow up CCTA (interval 2-5 years)

  4. Progression of low attenuation plaque volume (mm3)

    The progresison of total low attenuation plaque volume

    Time frame: Baseline (retrospective) and follow up CCTA (interval 2-5 years)

  5. Changes in coronary artery calcium score

    Change in the coronary artery calcium score

    Time frame: Baseline (retrospective) and follow up CCTA (interval 2-5 years)

  6. Changes in the number of high-risk plaque characteristics

    * Spotty calcium defined as punctate calcium within a plaque * Napkin ring sign defined in a non-calcified plaque cross sectional image by the presence of two or more features: a central area of low attenuation plaque that is apparently in contact with the lumen; and a ring like peripheral rim of higher CT attenuation surrounding his central area. * Positive remodeling, defined as the ratio of outer vessel diameter at the site of plaque divided by the average outer diameter of the proximal and distal vessel greater than 1.1. * Low attenuation plaque, defined as non-calcified plaque with internal attenuation less than 30 Hounsfield units (HU).

    Time frame: Baseline (retrospective) and follow up CCTA (interval 2-5 years)

  7. Changes in peri coronary fat attenuation index

    Change in the peri coronary fat attenuation index

    Time frame: Baseline (retrospective) and follow up CCTA (interval 2-5 years)

  8. The number of cardiovascular events

    The number of cardiovascular events consisting of: * Myocardial infarction (defined as the universal definition as established by the European Society of Cardiology (ESC), American College of Cardiology (ACC), American Heart Association (AHA) and the World health federation) * Cerebrovascular accidents (neurologic deficit lasting more than 24 hours or lasting less than 24 hours with a brain imaging study showing infarction) * Target vessel revascularization * CAD related hospitalization

    Time frame: Baseline (retrospective) and follow up CCTA (interval 2-5 years)

  9. The number of cardiovascular events

    Myocardial infarction (defined as the universal definition as established by the European Society of Cardiology (ESC), American College of Cardiology (ACC), American Heart Association (AHA) and the World health federation) * Cerebrovascular accidents (neurologic deficit lasting more than 24 hours or lasting less than 24 hours with a brain imaging study showing infarction) * Target vessel revascularization * CAD related hospitalization

    Time frame: Baseline CCTA untill 10 years follow up after inclusion

07

Study locations

1 of 2 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Oct 2026, 15 months after the start.

Of 436 non-industry observational studies under Diabetes Mellitus, Type 2, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 96. This study's planned 15 months is below that.

Counting every sponsor, half of 606 studies reached it within 32 months; a quarter within 17 and three quarters within 62.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 24, 2025
First posted
Nov 20, 2025
StartActual
Jun 6, 2025
Primary completionEst.
Oct 1, 2026
CompletionEst.
Oct 1, 2036
Last update
Nov 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07237685
Collaborators
Horizon Innovative Health Initiative, Novo Nordisk A/S, INSTITUTO DE INVESTIGACION BIOMEDICA DE SALAMANCA (IBSAL), Cardiology Centers of the Netherlands
Responsible party
M.M. Winter (Principal Investigator, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)) — Principal investigator
First posted
Nov 20, 2025
Start date
Jun 6, 2025
Primary completion
Oct 1, 2026 (estimated)
Completion
Oct 1, 2036 (estimated)
Last update
Nov 20, 2025

Study contacts

Willem R van de Vijver, MD
Contact
w.r.vandevijver@amsterdamumc.nl
+31205662402

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion